| Name | Title | Contact Details |
|---|
Supply Vision Inc. is a technology company providing Software as a Service (SaaS) solutions to the supply chain industry
Demostack is a demo experience platform that allows you to accelerate revenue with better product storytelling. You can spin up a sales demo environment in minutes, tailor the story, and win more deals faster.
CYPHER LEARNING is a company that specializes in providing learning platforms for schools, businesses, and entrepreneurs around the world. CYPHER LEARNING has three products: NEO LMS for Schools and Universities, MATRIX LMS for Businesses, and INDIE LMS for Entrepreneurs. CYPHER LEARNING is currently the only company that offers learning management systems in all major e-learning sectors: academic, corporate, and individuals. All products are known for their intuitive design, powerful features, and competitive pricing. The platforms are used by over 20,000 organizations, support 50+ languages, have millions of users, and have won several awards. CYPHER LEARNING headquarters are in Plano,TX. The company has offices all around the world in locations such as the USA, Mexico, Brazil, Spain, Romania, South Africa, India, the Philippines, Australia, Malaysia, Indonesia, Jordan, and more.
Complete source for baseball history including complete major league player, team, and league stats, awards, records, leaders, rookies and scores.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.